Top

International Journal of Clinical Oncology

Published in:

01-10-2018 | Original Article

A prospective feasibility study applying the ACOSOG Z0011 criteria to Japanese patients with early breast cancer undergoing breast-conserving surgery

Authors: Nobuyoshi Kittaka, Ryu Tokui, Chika Ota, Yoko Hashimoto, Kazuyoshi Motomura, Makoto Ishitobi, Takahiro Nakayama, Yasuhiro Tamaki

Published in: International Journal of Clinical Oncology | Issue 5/2018

Abstract

Background

In patients undergoing breast-conserving surgery and having positive sentinel lymph nodes (SLNs), the ACOSOG Z0011 trial showed equivalent loco-regional outcomes for patients receiving SLN dissection (SLND) alone and those receiving axillary lymph node dissection (ALND). We conducted a prospective single-arm study to confirm the applicability of the Z0011 criteria to Japanese patients with breast cancer.

Methods

Patients meeting the Z0011 inclusion criteria and providing consent to receive no additional ALND were prospectively enrolled at the Osaka International Cancer Institute from April 2012 to December 2016. Cumulative incidence of loco-regional recurrence was estimated and compared to that of the Z0011 study.

Results

Among a total of 881 patients who underwent breast-conserving surgery, 189 fulfilling the Z0011 criteria were enrolled and eligible for the subsequent analysis. Adjuvant chemotherapy was given to 113 (59.8%) patients, adjuvant hormone therapy to 170 (89.9%), and whole breast irradiation to 183 (96.8%). The frequency of tumors with positive lymphovascular invasion (p < 0.0001) and macrometastases in SLNs (p < 0.0001) were significantly higher in our study than in the Z0011 study. At the median follow-up of 36 months (range 10–64 months), only 2 of 189 patients (1.1%) experienced loco-regional recurrence. The 5-year cumulative rate of loco-regional recurrences was 1.3% (95% CI 0–3.1%), and the 3-year distant DFS rate was 96.8% (95% CI 94.0–99.6%).

Conclusions

Our prospective study showed that it is feasible to apply the Z0011 strategy to Japanese patients with clinically node-negative breast cancer undergoing breast-conserving surgery with planned whole breast irradiation.

Carter CL, Allen C, Henson DE (1989) Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases. Cancer 63:181–187CrossRefPubMed

Veronesi U, Paganelli G, Viale G et al (2003) A randomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer. N Engl J Med 349:546–553CrossRefPubMed

Giuliano AE, Hunt KK, Ballman KV et al (2011) Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. JAMA 305:569–575CrossRefPubMedPubMedCentral

Colleoni M, Sun Z, Price KN et al (2016) Annual hazard rates of recurrence for breast cancer during 24 years of follow-up: results from the international breast cancer study group trials I to V. J Clin Oncol 34:927–935CrossRefPubMedPubMedCentral

Giuliano AE, Ballman KV, McCall L et al (2017) Effect of axillary dissection vs no axillary dissection on 10-year overall survival among women with invasive breast cancer and sentinel node metastasis: the ACOSOG Z0011 (Alliance) randomized clinical trial. JAMA 318:918–926CrossRefPubMedPubMedCentral

Giuliano AE, Ballman K, McCall L et al (2016) Locoregional recurrence after sentinel lymph node dissection with or without axillary dissection in patients with sentinel lymph node metastases: long-term follow-up from the American College of Surgeons Oncology Group (Alliance) ACOSOG Z0011 randomized trial. Ann Surg 264:413–420CrossRefPubMedPubMedCentral

Caudle AS, Hunt KK, Kuerer HM et al (2011) Multidisciplinary considerations in the implementation of the findings from the American College of Surgeons Oncology Group (ACOSOG) Z0011 study: a practice-changing trial. Ann Surg Oncol 18:2407–2412CrossRefPubMedPubMedCentral

Delpech Y, Bricou A, Lousquy R et al (2013) The exportability of the ACOSOG Z0011 criteria for omitting axillary lymph node dissection after positive sentinel lymph node biopsy findings: a multicenter study. Ann Surg Oncol 20:2556–2561CrossRefPubMed

Yi M, Kuerer HM, Mittendorf EA et al (2013) Impact of the american college of surgeons oncology group Z0011 criteria applied to a contemporary patient population. J Am Coll Surg 216:105–113CrossRefPubMed

10.

Morrow M, Van Zee KJ, Patil S et al (2017) Axillary dissection and nodal irradiation can be avoided for most node-positive Z0011-eligible breast cancers: a prospective validation study of 793 patients. Ann Surg 266:457–462CrossRefPubMedPubMedCentral

11.

Bhoo-Pathy N, Yip CH, Hartman M et al (2013) Breast cancer research in Asia: adopt or adapt Western knowledge? Eur J Cancer 49:703–709CrossRefPubMed

12.

Murawa D, Hirche C, Dresel S et al (2009) Sentinel lymph node biopsy in breast cancer guided by indocyanine green fluorescence. Br J Surg 96:1289–1294CrossRefPubMed

13.

Llatjos M, Castella E, Fraile M et al (2002) Intraoperative assessment of sentinel lymph nodes in patients with breast carcinoma: accuracy of rapid imprint cytology compared with definitive histologic workup. Cancer 96:150–156CrossRefPubMed

14.

Sobin LH, Compton CC (2010) TNM seventh edition: what’s new, what’s changed: communication from the International Union Against Cancer and the American Joint Committee on Cancer. Cancer 116:5336–5339CrossRefPubMed

15.

Lyman GH, Temin S, Edge SB et al (2014) Sentinel lymph node biopsy for patients with early-stage breast cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 32:1365–1383CrossRefPubMed

16.

Gradishar WJ, Anderson BO, Balassanian R et al (2017) NCCN Guidelines Insights: Breast Cancer, Version 1.2017. J Natl Compr Canc Netw 15:433–451CrossRefPubMed

17.

Yu JI, Park W, Huh SJ et al (2010) Determining which patients require irradiation of the supraclavicular nodal area after surgery for N1 breast cancer. Int J Radiat Oncol Biol Phys 78:1135–1141CrossRefPubMed

18.

Bilimoria KY, Bentrem DJ, Hansen NM et al (2009) Comparison of sentinel lymph node biopsy alone and completion axillary lymph node dissection for node-positive breast cancer. J Clin Oncol 27:2946–2953CrossRefPubMed

19.

Galimberti V, Cole BF, Zurrida S et al (2013) Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23-01): a phase 3 randomised controlled trial. Lancet Oncol 14:297–305CrossRefPubMedPubMedCentral

20.

Donker M, van Tienhoven G, Straver ME et al (2014) Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial. Lancet Oncol 15:1303–1310CrossRefPubMedPubMedCentral

21.

Jagsi R, Chadha M, Moni J et al (2014) Radiation field design in the ACOSOG Z0011 (Alliance) trial. J Clin Oncol 32:3600–3606CrossRefPubMedPubMedCentral

22.

Early Breast Cancer Trialists’ Collaborative G (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365:1687–1717CrossRef

23.

Smith I, Procter M, Gelber RD et al (2007) 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet 369:29–36CrossRefPubMed

24.

Morrow M (2015) Rethinking the local therapy of breast cancer: integration of biology and anatomy. Ann Surg Oncol 22:3168–3173CrossRefPubMed

25.

Chung A, Gangi A, Mirocha J et al (2015) Applicability of the ACOSOG Z0011 criteria in women with high-risk node-positive breast cancer undergoing breast conserving surgery. Ann Surg Oncol 22:1128–1132CrossRefPubMed

Title: A prospective feasibility study applying the ACOSOG Z0011 criteria to Japanese patients with early breast cancer undergoing breast-conserving surgery
Authors: Nobuyoshi Kittaka
Ryu Tokui
Chika Ota
Yoko Hashimoto
Kazuyoshi Motomura
Makoto Ishitobi
Takahiro Nakayama
Yasuhiro Tamaki
Publication date: 01-10-2018
Publisher: Springer Japan
Published in: International Journal of Clinical Oncology / Issue 5/2018
Print ISSN: 1341-9625
Electronic ISSN: 1437-7772
DOI: https://doi.org/10.1007/s10147-018-1297-0

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 5/2018

Analysis of unexplained carcinoembryonic antigen elevation after curative treatment of locally advanced rectal cancer

Rapid decrease of serum alpha-fetoprotein and tumor volume predicts outcome in children with hepatoblastoma treated with neoadjuvant chemotherapy

In vivo detection of acute intracellular acidification in glioblastoma multiforme following a single dose of cariporide

Relationships between sunitinib plasma concentration and clinical outcomes in Japanese patients with metastatic renal cell carcinoma

Low expression of CD40L in tumor-free lymph node of oral cavity cancer related with poor prognosis

Influence of incomplete neoadjuvant chemotherapy on esophageal carcinoma

Keynote webinar | Spotlight on antibody–drug conjugates in cancer